| Bioactivity | Evinacumab (REGN1500) is a humanised anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia[1]. |
| Target | ANGPTL3. |
| In Vivo | Evinacumab (REGN1500) (10 mg/kg; s.c.; single) lowers serum TGs in normolipidemic C57Bl/6 mice and increases postheparin plasma LPL activity[1].Evinacumab (25 mg/kg; s.c.; once weekly for 8 weeks) lowers serum TG and cholesterol levels in dyslipidemic C57Bl/6 mice[1].Evinacumab (10 mg/kg; s.c.; single) lowers serum HDL-C by an EL-dependent mechanism in Lipg-/- mice[1]. Animal Model: |
| Name | Evinacumab |
| CAS | 1446419-85-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gusarova V, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015 Jul;56(7):1308-17. |